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Abstract
Background: Gram-negative bacteria are increasingly responsible for nosocomial infections, including ICU-acquired
infections. Due to high virulence, rate of multi-drug resistance and limited availability of new agents, these infections
create cumbersome clinical burdens, making it important to reduce the risk of their occurrence. The aim of the study
was to assess epidemiology-related factors and outcomes of Gram-negative, ICU-acquired infections in a cohort of
medical-surgical patients.
Methods: A retrospective survey was conducted on all patients admitted to a mixed ICU from January 2012 to
December 2013. ‘ICU-acquired infections’ were defined as new infections acquired no less than 48 h after ICU
admission. Diagnosis was made according to the Centers for Disease Control and Prevention National Healthcare
Safety Network (CDC/NHSN) criteria. Differences across patients who did and did not acquire a Gram-negative infection
were tested regarding age, sex, body mass index, medical or surgical admission, cardiovascular comorbidities, chronic
obstructive pulmonary disease, diabetes, end-stage renal failure, co-existing tumours and prophylactic anti-fungal
treatment. Multivariate analysis was used to assess the independency of these associations. Finally, differences in
ICU-mortality, ICU-length of stay and duration of mechanical ventilation were tested across patients with and without
new, ICU-acquired, Gram-negative infections.
Results: Of 494 patients admitted to the ICU, 46 (9.3 %) acquired an infection 48 or more hours after admittance.
In 30/46 patients (65.2 %) the isolated bacterium was Gram-negative. Univariate analysis showed that clinical
factors associated with new ICU-acquired Gram-negative infections were medical admission (p < 0.001, 95 % CI
0.59 – 0.29, OR = 0.13), chronic kidney disease (p = 0.018, 95 % CI 1.20 – 7.34, OR = 2.98) and prophylactic antifungal
therapy (p < 0.001, 95 % CI 1.91 – 9.79, OR = 4.33). At multivariate analysis, only medical admission and prophylactic
antifungal therapy were significantly associated with ICU-acquired Gram-negative infections. Higher ICU-length of stay
and longer duration of mechanical ventilation were associated with these infections while ICU-mortality did not
significantly differ.
Conclusions: ICU-acquired Gram-negative infections were common in a cohort of mixed medical-surgical patients. Only
medical admission and anti-fungal prophylaxis were found to be independently associated with these infections; they
were not found to have a significant effect on ICU-mortality.
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Background
Prevalence of infections in ICU patients worldwide is an
estimated 51.4 % [1]. Gram-negative bacteria are largely
responsible for ICU-acquired infections and extended-
(XDR) or multi-drug resistant (MDR) strains are increas-
ingly the ones isolated, including carbapenemase-producing
Klebsiella pneumoniae (KPC), Acinetobacter spp. and
Pseudomonas aeruginosa [2, 3]. Infections due to XDR/
MDR bacteria lead to higher ICU-mortality rates, increased
morbidity and increased healthcare costs, while only limited
therapeutic options are available [4–6]. There are many
reported risk factors for ICU-acquired infections. These
may include patient-related comorbidities such as dia-
betes mellitus or chronic respiratory conditions, and
nosocomial factors such as empiric use of fluoroquino-
lones, immunosuppression and the use of invasive
devices [7–9]. Interestingly, bacterial and fungal floras
may interact in the same patient, competing with each
other and reciprocally controlling each other’s growth
[10]. Candida albicans derived farnesol may inhibit the
growth of A. baumannii, E. coli, P. aeruginosa and S.
aureus [10]. Prophylactic use of antifungal drugs may
alter the bacterial-fungal balance and potentially con-
tribute to bacterial infections.
The aim of this study was to determine the epidemi-
ology of Gram-negative, ICU-acquired infections, to
assess the factors to acquisition, including prophylactic
use of antifungals, and to assess the effect of these infec-
tions on ICU mortality, ICU-length of stay and days of
mechanical ventilation.
Methods
Study design and setting
A monocentric, observational, retrospective study was
conducted for a cohort of patients admitted to a six-
bed mixed medical-surgical ICU of a tertiary referral
hospital between January 2012 and December 2013.
The institutional Ethical Board of Careggi University
Hospital (Florence, Italy) reviewed and approved this
protocol (n° 2013/0024940) and waived the need for
informed consent due to the retrospective nature of the
study. The study was designed following the indications
of STROBE guidelines.
Patients and definitions
Patients whose ICU-length of stay was longer than 48 h
were considered eligible for our study. ‘ICU-acquired
infections’ were defined as those acquired no less than
48 h after ICU admission. Clinical diagnosis was made
according to the criteria of the Centers for Disease Con-
trol and Prevention National Healthcare Safety Network
(CDC/NHSN) [11]. All microbiological isolates of infected
patients were evaluated. In cases where a patient acquired
more than one infection, the first diagnosed infection was
defined as ‘primary’ and the subsequent infections as ‘sec-
ondary’. ICU patients admitted for more than 48 h with-
out evidence of infection or those who acquired infections
prior to 48 h from admittance were treated as ‘controls’ in
the subsequent analysis.
Objectives
The first objective of this study was to assess the epi-
demiology of Gram-negative, ICU-acquired infections.
Epidemiology was described in terms of incidence of
new infections, aetiology, and site distribution.
The second objective was to assess which clinical fac-
tors were associated with these infections. Differences
between patients who did and did not acquire a Gram-
negative infection were tested according to a number of
demographic and clinical factors, including: age, sex,
body mass index, type of admission (medical/surgical), car-
diovascular comorbidities, chronic respiratory impairment,
diabetes mellitus, end-stage renal failure, co-existing tu-
mours (metastatic/non-metastatic), infection/sepsis at ICU
admittance and anti-fungal prophylaxis administered prior
to the Gram-negative infection. ‘Surgical’ patients were
defined as those who had surgery in the 24 h prior to ICU
admittance. All other patients were defined as ‘medical’.
Cardiovascular comorbidities included hypertension,
chronic heart failure, valvular disease and coronary artery
disease. ‘Chronic respiratory impairment’ was defined as
chronic respiratory failure inducing symptoms. ‘End-stage
renal failure’ was defined as the chronic need for dialysis.
‘Anti-fungal prophylaxis’ was defined as previous adminis-
tration of anti-fungal agents in the absence of microbio-
logical or serological evidence of fungal infection [12].
The third objective was to assess the outcomes of
patients with ICU-acquired Gram-negative infections. ICU
mortality, ICU-length of stay and duration of mechanical
ventilation were considered, and differences across patients
were tested.
Statistical analysis
The incidence of ICU-acquired Gram-negative infections
was described as a percentage. Patients who presented
with an ICU-acquired Gram-negative infection (the study
group) were retrospectively compared to remaining
patients (the control group). The normal distribution of
variables was evaluated using the Kolgorov-Smirnof test,
and the results of continuous variables were presented as
a mean ± standard deviation (SD). Categorical variables
were analysed using the chi-square test and presented as a
percentage.
Logistic regression analysis was performed to identify
characteristics that, ceteris paribus, were associated with
ICU-acquired Gram-negative infections and their relative
weighting. In particular, a forward analysis was conducted
in the observed population, starting from a null model and
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adding variables for the multivariate analysis. Results of
multivariate analysis were presented as a p-value and odds
ratio (OR) with 95 % confidence interval (95 % CI). Data
were analysed using the STATA 9.1 software (STATA Corp,
4905, Lakeway Drive College Station, 77845, Texas, US).
Results
Of the 494 patients enrolled in our study, 46 had an ICU-
acquired infection (9.3 % of patients). In 30 out of these
46 infections, the isolated pathogen responsible was a
Gram-negative bacterial strain (65.2 % of ICU-acquired
infections). In the other 16 cases, a Gram-positive strain
or a fungus were isolated.
The Gram-negative bacteria responsible for the primary
infections were: K. pneumoniae (30 % of ICU-acquired
Gram-negative infections), A. baumannii (20 %), E. coli
(20 %), P. aeruginosa (17 %) and in 13 % of cases the infec-
tions were caused by other Gram-negative bacteria such as
S. maltophilia, K. oxytoca, H. influenzae and Enterobacter
spp (Fig. 1). The infection sites were mostly the respiratory
tract (60 %), followed by catheter-related bacteraemia
(20 %), non-catheter-related bacteraemia (13 %) and cuta-
neous (including surgical wound) infections (7 %) (Fig. 2).
Secondary infections were most commonly caused by K.
pneumoniae (31.8 %), followed by P. aeruginosa (27.2 %),
A. baumannii (22.8 %) and E. coli (18.2 %), and found in
the respiratory tract (38.7 %), the bloodstream (25.8 %),
peritoneal fluid (19.3 %), surgical wound infections
(12.9 %) and the urinary tract (in only one patient).
Regarding antibiotics resistance rates, 90.4 % of isolated
strains of A. baumannii were multi-drug resistant, and
colistin was the only therapeutic option, while 81.8 % of
isolated strains of K. pneumoniae were KPC-producers.
Amongst patients who developed one or more ICU-
acquired infections due to Gram-negative bacteria, 40 %
had been admitted for non-surgical treatment vs 8.1 % in
the control group (p < 0.001); 23.4 % suffered from chronic
renal failure vs 9.3 % in the control group (p = 0.018); and
33.4 % had been treated with antifungal agents before
acquiring the Gram-negative ICU-acquired infections vs
10.3 % in the control group (p < 0.001) (Table 1).
Amongst patients admitted for surgical treatment, only
4.05 % (18/444) developed Gram-negative infections,
while 95.95 % did not. Conversely, 24.0 % (12/50) of
non-surgical patients developed Gram-negative infec-
tions, while 76.0 % did not.
The multivariate analysis showed that medical admission
to the ICU and previous antifungal therapy were independ-
ent factors associated with Gram-negative ICU-acquired
infections (p < 0.001, OR 7.12, 95 % CI 3.12 – 16.25 and
p = 0.001, OR 4.05, 95 % CI 1.71 – 9.58 respectively)
(Table 2). The average starting time from ICU-admission
and the duration of antifungal therapy administration
(expressed as days) between the Gram-negative group and
the control group were 1.5 ± 0.3 vs 1.4 ± 0.4 (p = 0.179)
and 7.1 ± 1.2 vs 6.8 ± 1.4 (p = 0.252), respectively.
The comparison of ICU-length of stay (10.26 ± 2.43
vs 4.42 ± 2.37) and duration of mechanical ventilation
(6.83 ± 1.53 vs 1.80 ± 2.42) showed that these were
higher in the case group than in the control group
(p < 0.001). However, no significant difference in mortality
rate was observed between the two groups (16.67 % in the
case group vs 12.39 % in the control group) (Table 3).
Discussion
The results of this study support the notion that the rate
of new ICU-acquired Gram-negative infections is still high
amongst a cohort of mixed medical-surgical patients, and
mostly due to MDR bacteria. The relevant clinical factors
independently associated with these infections were
Fig. 1 Primary ICU-acquired Gram-negative infections
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admission to ICU for medical reasons, chronic renal fail-
ure and fungal prophylaxis prior to bacterial infection.
More than 20 % of nosocomial infections are acquired
in ICUs, and sepsis is a leading cause of death among pa-
tients, particularly those admitted to general and surgical
ICUs [13]. In the Extended Prevalence of Infection in In-
tensive Care (EPIC II) study, the point prevalence of sepsis
in ICU was 51 % in a cohort of 13,796 adult patients from
75 countries. Interestingly, 71 % of patients were receiving
antibiotics on the day of study [1]. Infection in ICU was
an independent predictor of mortality, with an estimated
OR of 1.51 (p < .001) [1]. Data on the rate of new ICU-
acquired infections are more difficult to obtain, partially
because of non-homogeneous diagnostic criteria and dif-
ferent case-mixes. In a seven-year-long survey conducted
by the National Nosocomial Infection Surveillance System
on almost 500,000 patients admitted to 205 combined
medical-surgical ICUs, the rate of ICU-acquired infection
was 6.1 %, with surgical patients accounting for 50 % of
these [14]. Recently, a French retrospective survey on
patients over 80 years old showed a rate of ICU-acquired
infection of 16.5 %, versus a rate of 13.9 % for younger
patients [15]. In Italy, the 2006 surveillance program on
infection in ICUs reported an ICU-acquired infection rate
of 9.1 %, with MDR organisms accounting for more than
50 % of isolates and an associated ICU mortality rate close
to 30 % [16]. In Spain, a rate of 9.3 % was recently found
using data taken from 20 ICUs [17]. In our cohort, the
rate of new ICU-acquired infections was 9.3 %, which was
very close to that reported by Malacarne and colleagues.
[16]. The difference in infection rates could be at least
partially explained by the numbers of available beds in
different countries. France, for instance, has an average of
38.5 ICU beds per 100,000 people [13], which may expose
patients to the use of invasive devices that is invariably
associated with ICU-infections.
In our cohort, 65.2 % of ICU-acquired infections were
due to Gram-negative bacteria, with K. pmeumoniae,
Fig. 2 Sites of primary ICU-acquired Gram-negative infections
Table 1 Characteristics of the population
Total population Gram-negative group Control group p
Age 69.6 ± 13.9 66.9 ± 10.7 69.8 ± 14.0 0.273
Male sex 63.1 % 76.7 % 62.3 % 0.120
BMI 26.1 ± 5.6 26.5 ± 5.5 26.1 ± 5.6 0.675
Medical admission 10.1 % 40.0 % 8.1 % 0.000
Hypertension 58.1 % 66.7 % 57.5 % 0.329
Valvular disease 5.9 % 10.0 % 5.6 % 0.328
Coronary artery disease 21.0 % 26.7 % 19.4 % 0.438
Heart failure 10.1 % 10.0 % 10.1 % 0.982
COPD 24.7 % 33.4 % 24.1 % 0.261
Diabetes 22.7 % 33.4 % 22.0 % 0.155
Chronic kidney disease 10.1 % 23.4 % 9.3 % 0.018
Malignancy 58.5 % 43.4 % 59.5 % 0.086
Previous antifungal therapy 11.7 % 33.4 % 10.3 % 0.000
Infection(s) on admission 9.5 % 20.0 % 8.8 % 0.051
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A. baumannii, E. coli and P. aeruginosa accounting for
the vast majority of these (see Fig. 1). This finding was
the same for both primary and secondary ICU-acquired
infections. The most frequent types of infections were
respiratory, catheter-related bacteraemia, non-catheter
related bacteraemia, secondary peritonitis, surgical
wound infections and a few urinary tract infections (see
Fig. 2). Notably, 90.4 % of A. baumannii and 81.8 % of
K. pneumoniae isolated strains were MDR. These figures
are largely in line with data contained in current litera-
ture [18]. There is a wide consensus about the role of
Gram-negative bacteria in causing most ICU-acquired
infections. In the EPIC II study, the reported rate of
Gram-negative isolates among ICU patient with infections
was 62 %, with resistant Staphylococci, Acinetobacter,
Pseudomonas spp. and Candida spp. accounting for the
majority of these [1]. The high rate of Gram-negative
bacteria isolated from patients with ICU-acquired infec-
tion has a twofold clinical significance: a high prevalence
of MDR strains combined with limited therapeutic
options; and a higher associated mortality, particularly for
Gram-negative bacteraemia [13].
In the past years, Gram-positive bacteria, especially S.
aureus and Enterococcus spp., developed a worryingly
high rate of resistant strains. This led to intense efforts
being made to discover new antibiotics that are effective
against these microorganisms. New molecules active
against VRSA and VRE, such as telavancin, are now
available, and infections due to these pathogens, even
when severe, can still be treated [19]. On the contrary,
little or no progress has been made recently in the treat-
ment of multi-drug resistant Gram-negative infections,
even though they are currently a serious threat in many
ICUs [20]. The lack of new antibiotics has led to older
antimicrobial agents, such as colistin—formerly aban-
doned due to its toxicity profile—being considered. In
many settings, this molecule is the only antibiotic effect-
ive on A. baumannii or K. pneumoniae [21, 22].
Regarding the associated factors, we observed that
medical patients admitted to ICU were infected by
Gram-negative bacteria more frequently than surgical
patients. Actually, while 24.0 % (12/50) of medical pa-
tients developed Gram-negative infections, only 4.05 %
(18/444) of surgical patients did so. Considering that most
of the surgical patients did not develop a Gram-negative
infection, this variable could not be considered as “risk
factor” for this specific outcome, even if the absolute num-
ber of surgical cases with infection was higher than
medical (18 vs. 12), due to the mostly surgical compos-
ition of the cohort. These results may be explained by
the different clinical conditions for each group. Surgical
patients were usually admitted to the ICU for post-
operative management or, in the worst cases, for post-
surgical complications, while medical patients were more
often compromised, with many comorbidities, requiring
more intensive and invasive treatments. Chronic kidney
disease (CKD) was a factor associated with ICU-acquired
Gram-negative infections, although findings in the litera-
ture mostly concern Gram-positive infections [23, 24]. The
univariate analysis showed a double risk of infection in
patients suffering from this condition, but the multivariate
analysis did not confirm CKD as a factor independently
associated with Gram-negative infections. Other condi-
tions, such as the underlying causes of CKD itself (i.e., dia-
betes and hypertension) or hemodialysis, could therefore
play a role.
Interestingly, we found that patients who acquired
Gram-negative infections in ICU had been exposed to
antifungal prophylactic administration more frequently
than those who did not, and this turned out to be an in-
dependently associated factor. However, we did not find
any significant difference either in the average starting
time or in the duration of antifungal therapy administra-
tion between the Gram-negative group and the control
group (1.5 ± 0.3 vs 1.4 ± 0.4, p = 0.179 and 7.1 ± 1.2 vs
6.8 ± 1.4, p = 0.252 respectively). The association between
prior antifungal exposure and infection by Gram-negative
strains could be related to some forms of bacterial-fungal
interaction. Several studies show a variety of interactions
between bacterial species and Candida albicans, demon-
strated both in vitro and in animal models, which are
mediated by mechanisms that are still not fully under-
stood [10]. For instance, farnesol, a sesquiterpene mol-
ecule secreted by C. albicans, has been found to cause
numerous antagonistic interactions between the fungus
and various bacterial species. This molecule inhibits the
production of virulence factors and alters quorum sensing
of P. aeruginosa; it inhibits the viability of A. baumannii
Table 2 Multivariate analysis
Odds ratio P value 95 % conf. interval
Medical admission 7.12 0.000 3.12–16.25
Previous antifungal therapy 4.05 0.001 1.71–9.58
Table 3 Data on ICU outcome
Total population Gram-negative group Control group p
Days of mechanical ventilation 2.11 ± 2.7 6.83 ± 1.53 1.80 ± 2.42 <0.001
ICU length-of-stay 4.78 ± 2.75 10.26 ± 2.43 4.42 ± 2.37 <0.001
ICU- death 12.65 % 16.67 % 12.39 % NS
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in biofilms; and it can also raise the susceptibility of E. coli
and S. aureus to common antibacterial agents [25]. More-
over, emerging studies are investigating the field of
bacterial-fungal interactions as a possible source of new
therapeutic agents. In a recent paper, King et al. [26] show
how a natural fungal product, aspergillomarasmine A.,
can restore the sensitivity to carbapenems in resistant
strains of various pathogens by inhibiting NDM-1 and
VIM-2—two clinically relevant metallobetalactamases.
The available studies are mostly conducted in vitro or in
animal models, and very little is known about these inter-
actions in the clinical setting. To our knowledge, this is
the first study showing a potentially relevant clinical effect
of the indirect manipulation of these interactions with
antifungal treatment. Data on this issue are not homoge-
neous, and a few studies have found that C. albicans
colonization can be an independent risk factor for P. aeru-
ginosaVAP [27]. Treating patients colonized by C. albicans
may hence reduce the risk of P. aeruginosa VAP [28]. Our
results are in contrast with these findings. However, groups
of patients with different case-mixes may explain this
discrepancy. In our cohort, due to the high prevalence of
abdominal surgical septic patients, antifungals were
administered pre-emptively without clear evidence of
fungal colonization. Indeed, colonization by Candida spp.
is a common finding in the ICU, and the risk of an invasive
fungal infection often leads to an aggressive therapeutic
approach, particularly in post-surgical septic patients. We
suggest that an ‘over-liberal’ use of antifungal agents,
despite their potential benefit to patients at high risk of
fungal-related mortality, may have altered the bacterial flora
of certain patients, contributing to colonization and
subsequent infection by Gram-negative strains. Although
this finding needs to be confirmed by larger, prospective
studies, the association appears to be significant, and may
lead to the consideration of a more conservative approach
when deciding on the administration of pre-emptive anti-
fungal therapy in the ICU.
In this study, the outcomes of patients with a Gram-
negative infection were worse than those of non-infected
patients in terms of length of ICU stay and duration of
mechanical ventilation. Worse outcomes for critically ill
patients with sepsis are well established in the literature
[29, 30]. The mortality attributable to ICU-acquired
infections is under debate, since a variety of factors
(which are not always easily identified) can be influential
here. In terms of survival rates, the current study
showed no significant differences between infected and
non-infected patients, although this study may have been
underpowered to detect such a difference. Furthermore,
we considered ICU-length of stay and duration of mech-
anical ventilation as outcome factors—i.e. total duration of
stay in the ICU and total days of ventilation. Since these
two outcome variables are also potential iatrogenic risk
factors for infections, this result could reflect either a real
difference in outcome between the two groups or an asso-
ciation between prolonged ICU-length of stay, prolonged
mechanical ventilation and ICU-acquired infections. The
retrospective nature of the study makes this difficult to
ascertain.
Our study has several limitations. It was an observational,
retrospective study conducted on a small sample group and
involving a monocentric survey. Larger prospective studies
are required to confirm our results. The retrospective
nature of the study made it too difficult to obtain precise
data regarding the reciprocal timing of events such as the
discontinuation of mechanical ventilation and the collection
of cultural specimens. This potential inaccuracy led us to
consider some potential iatrogenic risk factors for
ICU-acquired infections as outcome data (ICU-length of
stay and duration of mechanical ventilation). For similar
reasons, we have not considered differences in the severity
of conditions on admission to the ICU as a potential factor
associated with infection.
Conclusions
In our cohort of patients, infections due to Gram-negative
bacteria were common (65.2 % of ICU-acquired infec-
tions), admission to the ICU for non-surgical treatment
and anti-fungal prophylaxis were found to be independ-
ently associated with these infections, and no significant
differences were found in ICU mortality rates between
infected and non-infected patients.
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